Usama Jazzar1, Shan Yong1, Zachary Klaassen2, Jinhai Huo3, Byron D Hughes4, Edgar Esparza4, Hemalkumar B Mehta4, Simon P Kim5,6, Douglas S Tyler4, Stephen J Freedland7, Ashish M Kamat8, Dwight V Wolf9, Stephen B Williams1. 1. Division of Urology, The University of Texas Medical Branch at Galveston, Galveston, Texas. 2. Department of Surgery, Section of Urology, Medical College of Georgia, Georgia Regents University, Augusta, Georgia. 3. Department of Health Services Research, Management and Policy, The University of Florida, Gainesville, Florida. 4. Department of Surgery, The University of Texas Medical Branch at Galveston, Galveston, Texas. 5. Urology Institute, Center for Health Care Quality and Outcomes, University Hospitals Case Western Medical Center, Case Western Reserve University, Cleveland, Ohio. 6. Cancer Outcomes and Public Policy Effectiveness Research Center, Yale University, New Haven, Connecticut. 7. Department of Urology, Cedars Sinai Medical Center, Los Angeles, California. 8. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9. Department of Psychiatry, The University of Texas Medical Branch at Galveston, Galveston, Texas.
Abstract
BACKGROUND: Treatments for muscle-invasive bladder cancer are multimodal, complex, and often carry significant risks of physical and psychological morbidity. The objectives of this study were to define the incidence and types of psychiatric illnesses diagnosed after treatment and to determine their impact on survival outcomes. METHODS: In total, 3709 patients who were diagnosed with clinical stage T2 through T4a bladder cancer from January 1, 2002, to December 31, 2011, from the Surveillance, Epidemiology, and End Results-Medicare were analyzed. Multivariable analysis and Cox proportional-hazards models were used to determine the predictors associated with psychiatric diagnosis and impact on survival outcomes. RESULTS: Of 3709 patients, 1870 (50.4%) were diagnosed with posttreatment psychiatric disorders. Patients who underwent radical cystectomy were identified as being at significantly greater risk of having a posttreatment psychiatric illness compared with those who received radiotherapy and/or chemotherapy (hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.07-1.31; P = .001). In adjusted analyses, diagnosis of a psychiatric disorder resulted in significantly worse overall survival (HR, 2.80; 95% CI, 2.47-3.17; P < .001) and cancer-specific survival (HR, 2.39; 95% CI, 2.05-2.78; P < .001). CONCLUSIONS: One-half of patients with muscle-invasive bladder cancer who underwent treatment were diagnosed with a psychiatric disorder, which resulted in worse survival outcomes compared with patients who did not have a posttreatment psychiatric diagnosis. This information can be used to inform interventions to educate patients with muscle-invasive bladder cancer regarding the impact of different treatments on mental health. Cancer 2018.
BACKGROUND: Treatments for muscle-invasive bladder cancer are multimodal, complex, and often carry significant risks of physical and psychological morbidity. The objectives of this study were to define the incidence and types of psychiatric illnesses diagnosed after treatment and to determine their impact on survival outcomes. METHODS: In total, 3709 patients who were diagnosed with clinical stage T2 through T4a bladder cancer from January 1, 2002, to December 31, 2011, from the Surveillance, Epidemiology, and End Results-Medicare were analyzed. Multivariable analysis and Cox proportional-hazards models were used to determine the predictors associated with psychiatric diagnosis and impact on survival outcomes. RESULTS: Of 3709 patients, 1870 (50.4%) were diagnosed with posttreatment psychiatric disorders. Patients who underwent radical cystectomy were identified as being at significantly greater risk of having a posttreatment psychiatric illness compared with those who received radiotherapy and/or chemotherapy (hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.07-1.31; P = .001). In adjusted analyses, diagnosis of a psychiatric disorder resulted in significantly worse overall survival (HR, 2.80; 95% CI, 2.47-3.17; P < .001) and cancer-specific survival (HR, 2.39; 95% CI, 2.05-2.78; P < .001). CONCLUSIONS: One-half of patients with muscle-invasive bladder cancer who underwent treatment were diagnosed with a psychiatric disorder, which resulted in worse survival outcomes compared with patients who did not have a posttreatment psychiatric diagnosis. This information can be used to inform interventions to educate patients with muscle-invasive bladder cancer regarding the impact of different treatments on mental health. Cancer 2018.
Authors: B A Mahal; G Inverso; A A Aizer; D R Ziehr; A S Hyatt; T K Choueiri; K E Hoffman; J C Hu; C J Beard; A V D'Amico; N E Martin; P F Orio; Q-D Trinh; P L Nguyen Journal: Ann Oncol Date: 2014-11-27 Impact factor: 32.976
Authors: Peter E Clark; Neeraj Agarwal; Matthew C Biagioli; Mario A Eisenberger; Richard E Greenberg; Harry W Herr; Brant A Inman; Deborah A Kuban; Timothy M Kuzel; Subodh M Lele; Jeff Michalski; Lance C Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Philippe E Spiess; Donald L Trump; Geoffrey Wile; Timothy G Wilson; Mary Dwyer; Maria Ho Journal: J Natl Compr Canc Netw Date: 2013-04-01 Impact factor: 11.908
Authors: Heather S L Jim; Kristin M Phillips; Sari Chait; Leigh Anne Faul; Mihaela A Popa; Yun-Hsiang Lee; Mallory G Hussin; Paul B Jacobsen; Brent J Small Journal: J Clin Oncol Date: 2012-08-27 Impact factor: 44.544
Authors: Brittany Barber; Jace Dergousoff; Linda Slater; Jeffrey Harris; Daniel O'Connell; Hamdy El-Hakim; Vincent L Biron; Nicholas Mitchell; Hadi Seikaly Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-03 Impact factor: 6.223
Authors: Danyon Anderson; Abrahim N Razzak; Matthew McDonald; David Cao; Jamal Hasoon; Omar Viswanath; Alan D Kaye; Ivan Urits Journal: Health Psychol Res Date: 2022-08-20
Authors: Rashid K Sayyid; Christopher J D Wallis; Kyle Dymanus; Usama Jazzar; Hanan Goldberg; Stephen B Williams; Zachary Klaassen Journal: Ann Transl Med Date: 2020-03
Authors: Ian J Cooke; Dattatraya Patil; Katherine Bobrek; Vikram Narayan; Viraj Master; Mark Rapaport; Christopher P Filson; Shreyas S Joshi Journal: Cancer Med Date: 2021-11-12 Impact factor: 4.452
Authors: Michael J Raphael; Rebecca Griffiths; Yingwei Peng; Sumit Gupta; D Robert Siemens; Claudio Soares; Christopher M Booth Journal: J Natl Cancer Inst Date: 2021-09-04 Impact factor: 13.506